Emerging fungal diseases

被引:285
作者
Nucci, M
Marr, KA
机构
[1] Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98109 USA
[2] Univ Fed Rio de Janeiro, Univ Hosp, Rio De Janeiro, Brazil
[3] Univ Washington, Seattle, WA 98195 USA
关键词
D O I
10.1086/432060
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The epidemiology of invasive fungal infection is evolving. Yeasts other than Candida albicans and molds other than Aspergillus fumigatus have emerged as significant causes of invasive mycoses in severely immunocompromised patients. Although, in some instances, these changes may be related to medical interventions, such as the use of antifungal agents in prophylaxis, in the majority of cases, they seem to be a consequence of changes in the host, such as more-severe immunosuppression or different types of immunosuppression impacting both risk periods and the infections that occur. These factors have altered the epidemiology of infection in organ transplant recipients, premature newborns, and critically ill patients. This review discusses the epidemiology of some fungal infections that have emerged in the past few years, with an emphasis on the potential factors associated with their emergence and on practical implications of these epidemiological changes.
引用
收藏
页码:521 / 526
页数:6
相关论文
共 52 条
  • [31] Fusarium infection in hematopoietic stem cell transplant recipients
    Nucci, M
    Marr, KA
    Queiroz-Telles, F
    Martins, CA
    Trabasso, P
    Costa, S
    Voltarelli, JC
    Colombo, AL
    Imhof, A
    Pasquini, R
    Maiolino, A
    Souza, CA
    Anaissie, E
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (09) : 1237 - 1242
  • [32] Emerging moulds:: Fusarium, Scedosporium and Zygomycetes in transplant recipients
    Nucci, M
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2003, 16 (06) : 607 - 612
  • [33] A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients
    Pappas, PG
    Rex, JH
    Lee, J
    Hamill, RJ
    Larsen, RA
    Powderly, W
    Kauffman, CA
    Hyslop, N
    Mangino, JE
    Chapman, S
    Horowitz, HW
    Edwards, JE
    Dismukes, WE
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (05) : 634 - 643
  • [34] Guidelines for treatment of candidiasis
    Pappas, PG
    Rex, JH
    Sobel, JD
    Filler, SG
    Dismukes, WE
    Walsh, TJ
    Edwards, JE
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (02) : 161 - 189
  • [35] PARK BJ, 2004, 44 INT C ANT AG CHEM, P411
  • [36] Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex
    Perfect, JR
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 : S401 - S408
  • [37] Voriconazole treatment for less-common, emerging, or refractory fungal infections
    Perfect, JR
    Marr, KA
    Walsh, TJ
    Greenberg, RN
    DuPont, B
    de la Torre-Cisneros, J
    Just-Nübling, G
    Schlamm, HT
    Lutsar, I
    Espinel-Ingroff, A
    Johnson, E
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (09) : 1122 - 1131
  • [38] Rare and emerging opportunistic fungal pathogens:: Concern for resistance beyond Candida albicans and Aspergillus fumigatus
    Pfaller, MA
    Diekema, DJ
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (10) : 4419 - 4431
  • [39] Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents:: A global assessment from the ARTEMIS antifungal surveillance program conducted in 2001 and 2002
    Pfaller, MA
    Messer, SA
    Boyken, L
    Tendolkar, S
    Hollis, RJ
    Diekema, DJ
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (07) : 3142 - 3146
  • [40] Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections:: SENTRY Antimicrobial Surveillance Program, 1997 to 2000
    Pfaller, MA
    Diekema, DJ
    Jones, RN
    Messer, SA
    Hollis, RJ
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (03) : 852 - 856